Passage Bio, Inc. - Special Call Transcript
Thank you all for joining us today. We are very excited to host the first of a series of discussions in our R&D webinar series. The first will obviously focus on our lead program, PBGM01 in GM1 gangliosidosis. And I can't tell you how excited we are for the opportunity to talk about both Passage Bio and we -- how we are continuing to execute our vision to fill the promise of gene therapies for CNS disorders.
In addition to myself and our Chief Medical Officer, Gary Romano, I am very pleased that joining us will be Jim Wilson, Director of the Gene Therapy Program at University of Pennsylvania and our Chief Scientific Adviser and obviously, Co-Founder of the company; as well as Christian Hinderer who is our Senior Research Director of Translational Research at the Gene Therapy Program.
Before we begin on Slide 2, I remind you that we will be making forward-looking statements and to refer to our SEC filings for additional information. On Slide 3, I want to pause briefly on the agenda. After I give a brief overview of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
